KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Other Non Operating Income readings, the most recent being -$10.4 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 1959.49% to -$10.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$14.6 million, a 2170.83% decrease, with the full-year FY2025 number at -$17.3 million, down 2603.9% from a year prior.
  • Other Non Operating Income hit -$10.4 million in Q4 2025 for Biocryst Pharmaceuticals, down from $35000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $56.1 million in Q4 2021 to a low of -$29.0 million in Q2 2023.
  • Median Other Non Operating Income over the past 5 years was -$122500.0 (2021), compared with a mean of $675625.0.
  • Biggest five-year swings in Other Non Operating Income: surged 5733.73% in 2021 and later tumbled 22084.09% in 2023.
  • Biocryst Pharmaceuticals' Other Non Operating Income stood at $56.1 million in 2021, then tumbled by 100.96% to -$538000.0 in 2022, then plummeted by 5293.87% to -$29.0 million in 2023, then skyrocketed by 98.26% to -$506000.0 in 2024, then crashed by 1959.49% to -$10.4 million in 2025.
  • The last three reported values for Other Non Operating Income were -$10.4 million (Q4 2025), $35000.0 (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.